INNOCARE (09969) surged over 3%, rising 3.5% to HK$18.63 with trading volume of HK$133 million at the time of writing. On the news front, INNOCARE plans to hold a board meeting on August 19 (next Tuesday) to approve interim results. CICC previously noted that INNOCARE's first-quarter revenue increased 1.3 times year-on-year, with net profit turning from loss to profit of 18 million yuan, exceeding the firm's expectations. This was primarily driven by high growth of the company's core product Orelabrutinib and recognition of upfront payments from the licensing agreement with Prolium. Considering INNOCARE's better-than-expected Orelabrutinib sales, the firm raised its profit forecasts for this year and next, narrowing expected losses from the original projections of 436 million yuan and 256 million yuan to 415 million yuan and 225 million yuan respectively. Orelabrutinib is a BTK inhibitor developed by INNOCARE primarily for treating chronic lymphoma, with its market share showing a gradual upward trend and occupying an important position in China's BTK inhibitor market. In 2024, Orelabrutinib sales revenue exceeded 1 billion yuan, growing 49.14% year-on-year, capturing a 30% market share in China's BTK inhibitor market.